Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
MWN-AI** Summary
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, is set to debut its new portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress in Chicago from March 22-24. This innovative device provides rapid, lab-quality results, enhancing the deployment of Blood Volume Analysis (BVA) across varied clinical environments. Faced with more than five million adult ICU admissions annually in the U.S., which contribute to over $100 billion in healthcare costs, Daxor's advancements aim to mitigate these financial burdens while improving patient care outcomes.
Michael Feldschuh, CEO and President of Daxor, highlighted the crucial findings from research supporting the efficacy of BVA, which has shown to improve clinical outcomes by altering fluid and red blood cell interventions in 44% of patients and reducing mortality rates by 66% within surgical intensive care units. The company believes that this new analyzer will significantly enhance healthcare efficiency by reducing ventilator time and hospital stays.
The SCCM is the largest nonprofit organization focused on critical care medicine, representing all professional components of the critical care team globally. Daxor’s commitment to addressing the challenge of accurately measuring blood volume—a critical factor in the management of conditions such as heart failure—is backed by 50 years of innovation and a dedicated manufacturing facility in the U.S. The company is poised for market expansion with its FDA-cleared BVA diagnostic system that delivers real-time data, allowing healthcare providers to make informed, individualized treatment decisions.
For more information about Daxor and its groundbreaking technology, visit Daxor.com.
MWN-AI** Analysis
Daxor Corporation (Nasdaq: DXR) is poised for a significant advancement in the healthcare sector with its recent announcement of a portable blood volume analyzer, set to debut at the SCCM 2026 Critical Care Congress. This innovation is not just a technical accomplishment; it represents a strategic pivot toward enhancing patient outcomes and addressing the financial burdens that accompany critical care management.
The global critical care market is characterized by escalating costs, with ICU admissions in the U.S. exceeding $100 billion annually. Daxor's portable blood volume analyzer aims to streamline fluid management in ICUs, which has been evidenced to reduce mortality rates significantly—66% in surgical settings, as stated by CEO Michael Feldschuh. Such impactful results, coupled with the device's rapid and lab-quality assessments, create a compelling value proposition that hospitals cannot overlook.
From an investment perspective, Daxor's innovation positions it favorably within a high-growth sector. The focus on precision fluid management aligns perfectly with the healthcare industry's transition toward value-based care. Investors should monitor the product's reception at the congress, as well as potential acquisition or partnership opportunities that may arise post-launch.
Moreover, the company’s ISO certification and a robust U.S.-based manufacturing facility signal operational readiness for increased production and distribution efforts. However, prospective investors should remain cognizant of potential market risks, including competition, regulatory hurdles, and the need for widespread physician acceptance.
Given Daxor's established history in blood volume measurement technology and the tangible advantages of its new device, the market sentiment is expected to be positive. A strategic approach could involve accumulating shares in anticipation of increased adoption rates and revenue growth stemming from improved patient care outcomes in the ICU setting.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay
Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24.
The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings. This streamlined workflow positions Daxor to address the high costs associated with the more than five million annual adult ICU admissions in the U.S., which currently exceed $100 billion in annual healthcare spending.
“Supported by extensive peer-reviewed studies, including a randomized controlled trial, Daxor’s BVA has demonstrated significant impact on patient outcomes—altering fluid and red blood cell interventions in 44% of cases and reducing mortality by 66% in surgical intensive care units,” said Michael Feldschuh, Daxor CEO and President. “This conference offers a strategic platform to highlight our new faster, portable analyzer. By providing a more accessible system, we are helping hospitals reshape patient care and improve healthcare economics by reducing ventilator days and hospital length of stay.”
About Society of Critical Care Medicine
The Society of Critical Care Medicine (SCCM) is the largest nonprofit medical organization dedicated to promoting excellence and consistency in the practice of critical care. With members in more than eighty countries, SCCM is the only organization that represents all professional components of the critical care team. The Society offers a variety of activities that ensure excellence in patient care, education, research, and advocacy.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
FAQ**
How does Daxor Corporation DXR plan to leverage its portable blood volume analyzer to enhance precision fluid management in ICUs and contribute to reducing mortality rates in critically ill patients?
What specific strategies is Daxor Corporation DXR implementing to address the high costs associated with ICU admissions and enhance the accessibility of Blood Volume Analysis across various clinical settings?
Can Daxor Corporation DXR provide insights on how its extensive peer-reviewed studies, including randomized controlled trials, support the effectiveness of its BVA technology in improving patient outcomes in surgical intensive care units?
How does Daxor Corporation DXR's new portable blood volume analyzer differentiate itself from existing solutions, and what are the projected impacts on hospital length of stay and overall healthcare economics for ICUs?
**MWN-AI FAQ is based on asking OpenAI questions about Daxor Corporation (NASDAQ: DXR).
NASDAQ: DXR
DXR Trading
1.55% G/L:
$11.475 Last:
4,891 Volume:
$11.475 Open:
